Research programme: cancer therapeutics - Hanmi PharmaceuticalsAlternative Names: BTK/JAK dual inhibitor - Hanmi; EGFR mutant selective inhibitors - Hanmi; IAP inhibitor - Hanmi; Inhibitors of apoptosis protein inhibitors - Hanmi
Latest Information Update: 05 Jul 2011
At a glance
- Originator Hanmi Pharmaceutical
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; Inhibitor of apoptosis protein inhibitors; Janus kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Jun 2011 Early research is ongoing in South Korea
- 09 Aug 2010 Early research in Cancer in South Korea (unspecified route)